AIDOT announced that its Cerviray AI, an AI-based cervical cancer diagnostic solution, will accelerate its global expansion through participation in the Ministry of Trade, Industry and Energy’s (MOTIE) overseas pilot project for innovative medical products.

Cerviray AI was officially registered as an innovative product by MOTIE in 2025, recognizing its technological excellence and public health value. Building on this designation, AIDOT has been conducting overseas pilots targeting public healthcare institutions worldwide.

The project aims to improve healthcare accessibility for women in Latin America and promote the adoption of Korean innovative medical technologies in global public health. Pilot activities will initially begin in Mexico and Chile, where preliminary clinical studies have already been successfully completed.

An AIDOT representative highlighted that local governments in these countries have submitted formal letters of intent to participate, and discussions are underway to integrate Cerviray AI into national cervical cancer screening programs.

Cerviray AI is the only MFDS Class III AI medical device in Korea with on-device AI analysis capabilities, capable of classifying cervical lesions into four stages—Normal, CIN1, CIN2/3, and Cancer—while accurately detecting lesion locations. This makes it uniquely suitable for deployment in both domestic and international healthcare settings.

AIDOT CEO Jaehun Jung stated,
“Cerviray AI will contribute to improving early cervical cancer screening for women in Latin America and serve as a model for the global adoption of Korean innovative medical devices in public healthcare.”

Through this pilot project, AIDOT aims to expand the reach of Korea’s innovative medical technologies and demonstrate the clinical value of on-device AI solutions in global public health.

Korea Economic TV / November 26, 2025 / Deputy Editor Jaejun Yang